Malignant Mesothelioma Market

Malignant Mesothelioma Market Study by Pemetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, and Other Drugs from 2024 to 2034

Analysis of Malignant Mesothelioma Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Malignant Mesothelioma Market Outlook (2024 to 2034)

The global malignant mesothelioma market size is estimated to be valued at US$ 561.9 million in 2024. The market is projected to register a promising CAGR of 7.6% to accumulate sales worth US$ 1,164.9 million by 2034.

Key players providing malignant mesothelioma therapeutics are expected to deploy tools like artificial intelligence, 3D printing, and nanotechnology for improved production efficiency. Thereby meeting the increasing demand for drugs/ medications to raise the patient's life expectancy.

Leading companies are also taking significant steps to develop novel products that offer improved efficacy and results. Thus increasing their reliability and preference among healthcare practitioners.

Factors Uplifting the Growth of Malignant Mesothelioma Market

Surging consumption habits related to tobacco and cigarettes, to reduce stress levels or for other purposes, have been observed as a primary factor behind increasing cases of malignant mesothelioma. People are becoming concerned for their health as the prevalence of malignant mesothelioma continues to escalate. Out of worry, people are taking precautions and diagnosis for early disease detection. Moreover, rising approvals for effective combined therapy are expected to favor malignant mesothelioma therapeutics.

Numerous active players are working in association with other organizations to discover the effects of combining several medications on malignant mesothelioma. Further, various firms are executing clinical studies concentrating on different combination medications owing to a lack of technique patents.

Report Attributes Details
Estimated Market Value (2024E) US$ 561.9 million
Forecasted Market Value (2034F) US$ 1,164.9 million
Projected Growth Rate (2024 to 2034) 7.6%CAGR
Pemetrexed and Combination Segment Growth Rate (2024 to 2034) 7.8% CAGR
Parental Segment Growth Rate (2024 to 2034) 7.6% CAGR
North America Market Share (2024) 37%
Latin America Market Share (2024) 11.9%
Key Companies Profiled in the Malignant Mesothelioma Industry Report
  • Merck KGaA
  • Novartis AG
  • Beckman Coulter Inc.
  • bioMerieux
  • Bio-Rad Laboratories, Inc
  • Danaher
  • Hologic
  • Gilead Sciences, Inc.
  • Emcure Pharmaceuticals Limited. (India)
  • Cipla Inc.
  • Hetero
  • Bausch Health Companies Inc.
  • Johnson & Johnson Private Limited
  • Mylan N.V.
  • Sun Pharmaceutical Industries Limited
  • AstraZeneca
  • Sanofi S.A.
  • Arena Pharmaceuticals, Inc.
  • ONO PHARMACEUTICAL CO., LTD
  • Others

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Trends Dictate the Malignant Mesothelioma Market?

“Increasing Research and Development Activities is Enhancing the Market Scope of Malignant Mesothelioma”

Leading firms are extensively investing in research and development activities to launch targeted therapies that focus on particular molecules or pathways engaged in the development and proliferation of cancer cells. Consequently, developing a positive outlook for malignant mesothelioma therapeutics. The launch of high-resolution CT scanning to detect abnormalities in certain body parts is also giving momentum to market expansion.

What are the Main Challenges that are Restricting the Market’s Growth?

“Unfavorable Aspects of Malignant Mesothelioma Drugs Like High Cost and Low Survival Rate”

Drugs prescribed for the treatment of malignant mesothelioma are heavy on pockets. This restricts its uptake in countries where income levels are average, and prospects for additional expenses are dim. In addition to this, the low survival rate offered by these drugs, which is usually five years or less, is also limiting the consumption of drugs intended for malignant mesothelioma.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Region-wise Insights

Which Region Captures Substantial Market Share in the Following Years?

“North America’s Share in the Market is Prominently High”

As per the recent market estimates, the North America malignant mesothelioma market is expected to acquire a massive value share of 37% in 2024. Revenue generated by this regional market is forecast to rise from US$ 208 million in 2024 to US$ 389 million by 2034. Demand for malignant mesothelioma therapeutics is projected to register a 6.5% CAGR during this period.

Growth in North America is expected to be driven by rising knowledge about drug and diagnostic procedures. Increasing cases of malignant mesothelioma and the rising availability of treatment options for people suffering from this disease are key factors that are driving the market forward.

Which Region is Expected to Register Higher Growth Rate?

“Latin America is Anticipated to Exhibit Promising Growth Potential in the Upcoming Years”

According to recent market predictions, the Latin America market for malignant mesothelioma is expected to obtain a small share of 11.9% in 2024. The adoption rate for malignant mesothelioma therapeutics, however, is expected to witness intensified growth. Through 2034, this regional market is projected to record a 9.4% CAGR.

Rising prevalence of cancer and surging cognizance about present cancer treatment methods are anticipated to drive up the market demand. The development of advanced therapies is further expected to elevate the market’s scope.

Country-wise Insights

Which Country in North America Dominates the Regional Sphere?

“The United States is Forecast to Lead with a Share of 68.1% in North America”

The United States malignant mesothelioma market is estimated to attain US$ 141 million in 2024. With a projected CAGR of 6.4%, the market is forecast to attain a valuation of US$ 264 million by 2034.

The expansion of malignant mesothelioma industry in the United States is backed by an increasing count of leading players as well as rising spending on research and development. Additionally, significant investments in the healthcare sector and the availability of expert doctors are boosting medical tourism in the country. Thus surging the prospects for malignant mesothelioma industry players.

Which Country is Anticipated to Accelerate at a Promising Pace?

“Chile is Expected to Observe Flourishing Growth Rate”

Chile is expected to register a CAGR of 9.5% over the forecast period. The country is witnessing a significant rise in cases of malignant mesothelioma, which is creating a heightened demand for malignant mesothelioma therapeutics. Chile is expected to occupy a 65.3% share of Latin America in 2024. In the same year, the country is estimated to capture a market value of US$ 44 million.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Segment-wise Insights

Which Drug Type Captures a Considerable Market Share?

“Pemetrexed and Combination Gains a Leading Position in the Malignant Mesothelioma Market”

The pemetrexed and combination drug type enjoys a leading stance, occupying a share of 49.8% in 2024. Sales of pemetrexed and combination drugs are estimated to generate a revenue of US$ 280.0 million in 2024. Recording a purchase rate of 7.8% CAGR, pemetrexed and combination drugs are forecast to attain US$ 596.0 million by 2034. This segment’s growth hinges on the rising clinical trials by key players and related organizations to discover more effective pemetrexed and combination drugs.

Which Route of Administration is Highly Preferred?

“Parenteral Route of Administration is Substantially Preferred by Patients and Medical Professionals Alike”

The parenteral route of administration is expected to obtain a value share of 92.2% in 2024. Sales generated by this administration mode are estimated to be US$ 518.2 million in 2024. By 2034, the segment is forecast to attain US$ 1,075.7 million on the back of a 7.6% CAGR.

Increasing concerns over the full absorption of drugs and sufficient drug delivery to the tumor site are propelling the demand for the parenteral segment. This route of administration ensures a stronger therapeutic effect in comparison to oral medications.

Which Distribution Channel is Sought Frequently for Malignant Mesothelioma Medications?

“Individuals Prefer Purchasing Medications for Malignant Mesothelioma from Hospital Pharmacies”

The hospital pharmacy segment is expected to capture a dominant market share of 51.3% in 2024. The segment is estimated to be valued at US$ 288.4 million in 2024, and for 2034, it is forecast to reach US$ 618.4 million. In the meantime, the segment growth is projected to be 7.9% CAGR. Growing drug purchases for malignant mesothelioma from hospital pharmacies, due to their accessibility, is appreciating this segment’s value.

Competitive Landscape

Key players in the malignant mesothelioma market are investing in research and development activities for novel mesothelioma treatments, such as immunotherapy drugs, targeted therapies, and combination therapies, to provide significant benefits. Additionally, market leaders are optimizing their present drugs via formulations to reduce their side effects, improve their efficacy, and develop better delivery systems for effective differentiation.

Industry participants are creating and commercializing advanced diagnostic tools to detect malignant mesothelioma to enhance patient outcomes and market size. In tandem with this, players are charting new territories where the incidence rate for this disease is rising. Presently, markets in focus are Latin America and Asia Pacific, in addition to established markets.

Market contenders are also collaborating with patient advocacy groups, research institutions, and other healthcare providers to expand their reach, improve brand image, and increase research efficiency. Acquisitions and mergers with smaller or same-sized companies are also facilitating market consolidation.

Recent Developments in the Malignant Mesothelioma Market

  • In June 2023, Amneal Pharmaceuticals, Inc. announced that it had received 505(b)(2) New Drug Application (NDA) permission from the United States FDA. This product is the first and single ready-to-use demonstration of pemetrexed for injection and requires no dilution, reconstitution, or refrigeration. This injectable is used to treat malignant pleural mesothelioma and non-squamous non-small cell lung cancer.
  • In May 2023, researchers concluded that quinacrine, which is an antimalarial drug when applied to mesothelioma cells, can safeguard intense tumors from developing new blood vessels and causing cell death.
  • In April 2023, the FDA presented fast-track designation to SynKIR-110, a novel T-Cell therapy, for the treatment of patients suffering from mesothelioma. It is an important milestone for the company as it acknowledges the efforts made by the firm to bring this life-saving drug to patients requiring new treatment options.
  • In October 2020, the FDA granted permission to Opdivo (nivolumab) combined with Yervoy (ipilimumab) to treat mesothelioma. This drug combination is used as first-line treatment for adults suffering from malignant pleural mesothelioma. In 16 years, this is the first drug regimen which has been permitted for mesothelioma.

Segmentation of Malignant Mesothelioma Market Research

  • By Drug Type:

    • Pemetrexed and combination
    • Cisplatin and combination
    • Carboplatin and combination
    • Gemcitabine and combination
    • Vinorelbine and combination
    • Others combinations
  • By Route of Administration:

    • Oral
    • Parenteral
  • By Distribution Channel:

    • Hospital Pharmacies
    • Retail Pharmacies
    • Oncology Centers
  • By Region:

    • North America
    • Europe
    • Latin America
    • East Asia
    • South Asia and Oceania
    • The Middle East and Africa

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2019-2023 and Forecast, 2024-2034

    4.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Analysis, 2019-2023

    4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units Pack) Projections, 2024-2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Analysis By Drug Type, 2019-2023

    5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units Pack) Analysis and Forecast By Drug Type, 2024-2034

        5.3.1. Pemetrexed

        5.3.2. Cisplatin

        5.3.3. Carboplatin

        5.3.4. Gemcitabine

        5.3.5. Vinorelbine

        5.3.6. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2019-2023

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2024-2034

6. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Analysis By Route of Administration, 2019-2023

    6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units Pack) Analysis and Forecast By Route of Administration, 2024-2034

        6.3.1. Oral

        6.3.2. Parenteral

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019-2023

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024-2034

7. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Analysis By Region, 2019-2023

    7.3. Current Market Size Value (US$ Mn) & Volume (Units Pack) Analysis and Forecast By Region, 2024-2034

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2019-2023 and Forecast 2024-2034, By Country

    8.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023

    8.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Drug Type

        8.2.3. By Route of Administration

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Type

        8.3.3. By Route of Administration

    8.4. Key Takeaways

9. Latin America Market Analysis 2019-2023 and Forecast 2024-2034, By Country

    9.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023

    9.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Type

        9.2.3. By Route of Administration

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Route of Administration

    9.4. Key Takeaways

10. Western Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country

    10.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023

    10.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Drug Type

        10.2.3. By Route of Administration

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Route of Administration

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country

    11.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023

    11.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Drug Type

        11.2.3. By Route of Administration

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Route of Administration

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2019-2023 and Forecast 2024-2034, By Country

    12.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023

    12.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Drug Type

        12.2.3. By Route of Administration

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Route of Administration

    12.4. Key Takeaways

13. East Asia Market Analysis 2019-2023 and Forecast 2024-2034, By Country

    13.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023

    13.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Type

        13.2.3. By Route of Administration

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Route of Administration

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2034, By Country

    14.1. Historical Market Size Value (US$ Mn) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019-2023

    14.2. Market Size Value (US$ Mn) & Volume (Units Pack) Forecast By Market Taxonomy, 2024-2034

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Type

        14.2.3. By Route of Administration

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Route of Administration

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2023

            15.1.2.1. By Drug Type

            15.1.2.2. By Route of Administration

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2023

            15.2.2.1. By Drug Type

            15.2.2.2. By Route of Administration

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2023

            15.3.2.1. By Drug Type

            15.3.2.2. By Route of Administration

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2023

            15.4.2.1. By Drug Type

            15.4.2.2. By Route of Administration

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2023

            15.5.2.1. By Drug Type

            15.5.2.2. By Route of Administration

    15.6. U.K.

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2023

            15.6.2.1. By Drug Type

            15.6.2.2. By Route of Administration

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2023

            15.7.2.1. By Drug Type

            15.7.2.2. By Route of Administration

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2023

            15.8.2.1. By Drug Type

            15.8.2.2. By Route of Administration

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2023

            15.9.2.1. By Drug Type

            15.9.2.2. By Route of Administration

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2023

            15.10.2.1. By Drug Type

            15.10.2.2. By Route of Administration

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2023

            15.11.2.1. By Drug Type

            15.11.2.2. By Route of Administration

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2023

            15.12.2.1. By Drug Type

            15.12.2.2. By Route of Administration

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2023

            15.13.2.1. By Drug Type

            15.13.2.2. By Route of Administration

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2023

            15.14.2.1. By Drug Type

            15.14.2.2. By Route of Administration

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2023

            15.15.2.1. By Drug Type

            15.15.2.2. By Route of Administration

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2023

            15.16.2.1. By Drug Type

            15.16.2.2. By Route of Administration

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2023

            15.17.2.1. By Drug Type

            15.17.2.2. By Route of Administration

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2023

            15.18.2.1. By Drug Type

            15.18.2.2. By Route of Administration

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2023

            15.19.2.1. By Drug Type

            15.19.2.2. By Route of Administration

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2023

            15.20.2.1. By Drug Type

            15.20.2.2. By Route of Administration

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2023

            15.21.2.1. By Drug Type

            15.21.2.2. By Route of Administration

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2023

            15.22.2.1. By Drug Type

            15.22.2.2. By Route of Administration

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2023

            15.23.2.1. By Drug Type

            15.23.2.2. By Route of Administration

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Type

        16.3.3. By Route of Administration

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Merck & Co., Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

                17.1.1.5.2. Product Strategy

                17.1.1.5.3. Channel Strategy

        17.1.2. Novartis AG

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

                17.1.2.5.2. Product Strategy

                17.1.2.5.3. Channel Strategy

        17.1.3. Pfizer Inc.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

                17.1.3.5.2. Product Strategy

                17.1.3.5.3. Channel Strategy

        17.1.4. Sanofi

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

                17.1.4.5.2. Product Strategy

                17.1.4.5.3. Channel Strategy

        17.1.5. Eli Lilly and Company

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

                17.1.5.5.2. Product Strategy

                17.1.5.5.3. Channel Strategy

        17.1.6. Teva Pharmaceuticals

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

                17.1.6.5.2. Product Strategy

                17.1.6.5.3. Channel Strategy

        17.1.7. Sun Pharmaceuticals Industries Ltd

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

                17.1.7.5.2. Product Strategy

                17.1.7.5.3. Channel Strategy

        17.1.8. Corden Pharma International GmbH

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

                17.1.8.5.2. Product Strategy

                17.1.8.5.3. Channel Strategy

        17.1.9. Concordia International Corp

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

                17.1.9.5.2. Product Strategy

                17.1.9.5.3. Channel Strategy

        17.1.10. Polaris Pharmaceuticals, Inc

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

                17.1.10.5.2. Product Strategy

                17.1.10.5.3. Channel Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 1: Global Market Value (US$ Mn) Forecast by Region, 2019-2034

Table 2: Global Market Volume (Units Pack) Forecast by Region, 2019-2034

Table 3: Global Market Value (US$ Mn) Forecast by Drug Type, 2019-2034

Table 4: Global Market Volume (Units Pack) Forecast by Drug Type, 2019-2034

Table 5: Global Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034

Table 6: Global Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034

Table 7: North America Market Value (US$ Mn) Forecast by Country, 2019-2034

Table 8: North America Market Volume (Units Pack) Forecast by Country, 2019-2034

Table 9: North America Market Value (US$ Mn) Forecast by Drug Type, 2019-2034

Table 10: North America Market Volume (Units Pack) Forecast by Drug Type, 2019-2034

Table 11: North America Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034

Table 12: North America Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034

Table 13: Latin America Market Value (US$ Mn) Forecast by Country, 2019-2034

Table 14: Latin America Market Volume (Units Pack) Forecast by Country, 2019-2034

Table 15: Latin America Market Value (US$ Mn) Forecast by Drug Type, 2019-2034

Table 16: Latin America Market Volume (Units Pack) Forecast by Drug Type, 2019-2034

Table 17: Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034

Table 18: Latin America Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034

Table 19: Western Europe Market Value (US$ Mn) Forecast by Country, 2019-2034

Table 20: Western Europe Market Volume (Units Pack) Forecast by Country, 2019-2034

Table 21: Western Europe Market Value (US$ Mn) Forecast by Drug Type, 2019-2034

Table 22: Western Europe Market Volume (Units Pack) Forecast by Drug Type, 2019-2034

Table 23: Western Europe Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034

Table 24: Western Europe Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034

Table 25: Eastern Europe Market Value (US$ Mn) Forecast by Country, 2019-2034

Table 26: Eastern Europe Market Volume (Units Pack) Forecast by Country, 2019-2034

Table 27: Eastern Europe Market Value (US$ Mn) Forecast by Drug Type, 2019-2034

Table 28: Eastern Europe Market Volume (Units Pack) Forecast by Drug Type, 2019-2034

Table 29: Eastern Europe Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034

Table 30: Eastern Europe Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034

Table 31: South Asia and Pacific Market Value (US$ Mn) Forecast by Country, 2019-2034

Table 32: South Asia and Pacific Market Volume (Units Pack) Forecast by Country, 2019-2034

Table 33: South Asia and Pacific Market Value (US$ Mn) Forecast by Drug Type, 2019-2034

Table 34: South Asia and Pacific Market Volume (Units Pack) Forecast by Drug Type, 2019-2034

Table 35: South Asia and Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034

Table 36: South Asia and Pacific Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034

Table 37: East Asia Market Value (US$ Mn) Forecast by Country, 2019-2034

Table 38: East Asia Market Volume (Units Pack) Forecast by Country, 2019-2034

Table 39: East Asia Market Value (US$ Mn) Forecast by Drug Type, 2019-2034

Table 40: East Asia Market Volume (Units Pack) Forecast by Drug Type, 2019-2034

Table 41: East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034

Table 42: East Asia Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034

Table 43: Middle East and Africa Market Value (US$ Mn) Forecast by Country, 2019-2034

Table 44: Middle East and Africa Market Volume (Units Pack) Forecast by Country, 2019-2034

Table 45: Middle East and Africa Market Value (US$ Mn) Forecast by Drug Type, 2019-2034

Table 46: Middle East and Africa Market Volume (Units Pack) Forecast by Drug Type, 2019-2034

Table 47: Middle East and Africa Market Value (US$ Mn) Forecast by Route of Administration, 2019-2034

Table 48: Middle East and Africa Market Volume (Units Pack) Forecast by Route of Administration, 2019-2034

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 1: Global Market Value (US$ Mn) by Drug Type, 2024-2034

Figure 2: Global Market Value (US$ Mn) by Route of Administration, 2024-2034

Figure 3: Global Market Value (US$ Mn) by Region, 2024-2034

Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2019-2034

Figure 5: Global Market Volume (Units Pack) Analysis by Region, 2019-2034

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024-2034

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024-2034

Figure 8: Global Market Value (US$ Mn) Analysis by Drug Type, 2019-2034

Figure 9: Global Market Volume (Units Pack) Analysis by Drug Type, 2019-2034

Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034

Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034

Figure 12: Global Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034

Figure 13: Global Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034

Figure 14: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 15: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 16: Global Market Attractiveness by Drug Type, 2024-2034

Figure 17: Global Market Attractiveness by Route of Administration, 2024-2034

Figure 18: Global Market Attractiveness by Region, 2024-2034

Figure 19: North America Market Value (US$ Mn) by Drug Type, 2024-2034

Figure 20: North America Market Value (US$ Mn) by Route of Administration, 2024-2034

Figure 21: North America Market Value (US$ Mn) by Country, 2024-2034

Figure 22: North America Market Value (US$ Mn) Analysis by Country, 2019-2034

Figure 23: North America Market Volume (Units Pack) Analysis by Country, 2019-2034

Figure 24: North America Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 25: North America Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 26: North America Market Value (US$ Mn) Analysis by Drug Type, 2019-2034

Figure 27: North America Market Volume (Units Pack) Analysis by Drug Type, 2019-2034

Figure 28: North America Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034

Figure 29: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034

Figure 30: North America Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034

Figure 31: North America Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034

Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 34: North America Market Attractiveness by Drug Type, 2024-2034

Figure 35: North America Market Attractiveness by Route of Administration, 2024-2034

Figure 36: North America Market Attractiveness by Country, 2024-2034

Figure 37: Latin America Market Value (US$ Mn) by Drug Type, 2024-2034

Figure 38: Latin America Market Value (US$ Mn) by Route of Administration, 2024-2034

Figure 39: Latin America Market Value (US$ Mn) by Country, 2024-2034

Figure 40: Latin America Market Value (US$ Mn) Analysis by Country, 2019-2034

Figure 41: Latin America Market Volume (Units Pack) Analysis by Country, 2019-2034

Figure 42: Latin America Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 43: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 44: Latin America Market Value (US$ Mn) Analysis by Drug Type, 2019-2034

Figure 45: Latin America Market Volume (Units Pack) Analysis by Drug Type, 2019-2034

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034

Figure 48: Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034

Figure 49: Latin America Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034

Figure 50: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 51: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 52: Latin America Market Attractiveness by Drug Type, 2024-2034

Figure 53: Latin America Market Attractiveness by Route of Administration, 2024-2034

Figure 54: Latin America Market Attractiveness by Country, 2024-2034

Figure 55: Western Europe Market Value (US$ Mn) by Drug Type, 2024-2034

Figure 56: Western Europe Market Value (US$ Mn) by Route of Administration, 2024-2034

Figure 57: Western Europe Market Value (US$ Mn) by Country, 2024-2034

Figure 58: Western Europe Market Value (US$ Mn) Analysis by Country, 2019-2034

Figure 59: Western Europe Market Volume (Units Pack) Analysis by Country, 2019-2034

Figure 60: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 61: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 62: Western Europe Market Value (US$ Mn) Analysis by Drug Type, 2019-2034

Figure 63: Western Europe Market Volume (Units Pack) Analysis by Drug Type, 2019-2034

Figure 64: Western Europe Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034

Figure 65: Western Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034

Figure 66: Western Europe Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034

Figure 67: Western Europe Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034

Figure 68: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 69: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 70: Western Europe Market Attractiveness by Drug Type, 2024-2034

Figure 71: Western Europe Market Attractiveness by Route of Administration, 2024-2034

Figure 72: Western Europe Market Attractiveness by Country, 2024-2034

Figure 73: Eastern Europe Market Value (US$ Mn) by Drug Type, 2024-2034

Figure 74: Eastern Europe Market Value (US$ Mn) by Route of Administration, 2024-2034

Figure 75: Eastern Europe Market Value (US$ Mn) by Country, 2024-2034

Figure 76: Eastern Europe Market Value (US$ Mn) Analysis by Country, 2019-2034

Figure 77: Eastern Europe Market Volume (Units Pack) Analysis by Country, 2019-2034

Figure 78: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 79: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 80: Eastern Europe Market Value (US$ Mn) Analysis by Drug Type, 2019-2034

Figure 81: Eastern Europe Market Volume (Units Pack) Analysis by Drug Type, 2019-2034

Figure 82: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034

Figure 83: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034

Figure 84: Eastern Europe Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034

Figure 85: Eastern Europe Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034

Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 88: Eastern Europe Market Attractiveness by Drug Type, 2024-2034

Figure 89: Eastern Europe Market Attractiveness by Route of Administration, 2024-2034

Figure 90: Eastern Europe Market Attractiveness by Country, 2024-2034

Figure 91: South Asia and Pacific Market Value (US$ Mn) by Drug Type, 2024-2034

Figure 92: South Asia and Pacific Market Value (US$ Mn) by Route of Administration, 2024-2034

Figure 93: South Asia and Pacific Market Value (US$ Mn) by Country, 2024-2034

Figure 94: South Asia and Pacific Market Value (US$ Mn) Analysis by Country, 2019-2034

Figure 95: South Asia and Pacific Market Volume (Units Pack) Analysis by Country, 2019-2034

Figure 96: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 97: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 98: South Asia and Pacific Market Value (US$ Mn) Analysis by Drug Type, 2019-2034

Figure 99: South Asia and Pacific Market Volume (Units Pack) Analysis by Drug Type, 2019-2034

Figure 100: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034

Figure 101: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034

Figure 102: South Asia and Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034

Figure 103: South Asia and Pacific Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034

Figure 104: South Asia and Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 105: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 106: South Asia and Pacific Market Attractiveness by Drug Type, 2024-2034

Figure 107: South Asia and Pacific Market Attractiveness by Route of Administration, 2024-2034

Figure 108: South Asia and Pacific Market Attractiveness by Country, 2024-2034

Figure 109: East Asia Market Value (US$ Mn) by Drug Type, 2024-2034

Figure 110: East Asia Market Value (US$ Mn) by Route of Administration, 2024-2034

Figure 111: East Asia Market Value (US$ Mn) by Country, 2024-2034

Figure 112: East Asia Market Value (US$ Mn) Analysis by Country, 2019-2034

Figure 113: East Asia Market Volume (Units Pack) Analysis by Country, 2019-2034

Figure 114: East Asia Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 115: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 116: East Asia Market Value (US$ Mn) Analysis by Drug Type, 2019-2034

Figure 117: East Asia Market Volume (Units Pack) Analysis by Drug Type, 2019-2034

Figure 118: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034

Figure 119: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034

Figure 120: East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034

Figure 121: East Asia Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034

Figure 122: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 123: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 124: East Asia Market Attractiveness by Drug Type, 2024-2034

Figure 125: East Asia Market Attractiveness by Route of Administration, 2024-2034

Figure 126: East Asia Market Attractiveness by Country, 2024-2034

Figure 127: Middle East and Africa Market Value (US$ Mn) by Drug Type, 2024-2034

Figure 128: Middle East and Africa Market Value (US$ Mn) by Route of Administration, 2024-2034

Figure 129: Middle East and Africa Market Value (US$ Mn) by Country, 2024-2034

Figure 130: Middle East and Africa Market Value (US$ Mn) Analysis by Country, 2019-2034

Figure 131: Middle East and Africa Market Volume (Units Pack) Analysis by Country, 2019-2034

Figure 132: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 133: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 134: Middle East and Africa Market Value (US$ Mn) Analysis by Drug Type, 2019-2034

Figure 135: Middle East and Africa Market Volume (Units Pack) Analysis by Drug Type, 2019-2034

Figure 136: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Type, 2024-2034

Figure 137: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Type, 2024-2034

Figure 138: Middle East and Africa Market Value (US$ Mn) Analysis by Route of Administration, 2019-2034

Figure 139: Middle East and Africa Market Volume (Units Pack) Analysis by Route of Administration, 2019-2034

Figure 140: Middle East and Africa Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 141: Middle East and Africa Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 142: Middle East and Africa Market Attractiveness by Drug Type, 2024-2034

Figure 143: Middle East and Africa Market Attractiveness by Route of Administration, 2024-2034

Figure 144: Middle East and Africa Market Attractiveness by Country, 2024-2034

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

What was the Value of the Malignant Mesothelioma Market in 2019?

The global malignant mesothelioma market was worth US$ 387.5 million in 2019.

What is the Sales Outlook for Malignant Mesothelioma in 2024?

The sales outlook for malignant mesothelioma is likely to be valued at US$ 561.9 million in 2024.

What is the Demand Forecast for Malignant Mesothelioma for the Decade?

Demand for malignant mesothelioma is forecast to reach a market value of US$ 1,164.9 million by the end of 2034

What is the Growth Projection for the Malignant Mesothelioma Market?

The market for malignant mesothelioma is projected to rise at a CAGR of 7.6% through 2034.

At What Rate Is the Market In Latin America Predicted to Grow?

The Latin America market for malignant mesothelioma is likely to expand at a CAGR of 9.4% through 2034.

- Also of Interest -

Analysis of Medical Tourism Industry in Malaysia

Study on Medical Tourism in Malaysia by Cardiovascular, Oncology, Fertility, Orthopedic, Dental, Ophthalmology, Aesthetics/Cosmetics, Neurology, Regenerative, and Medical Check-ups from 2024 to 2034

3D Printing Medical Device Market

3D Printing Medical Device Market Study by 3D Printers, 3D Bio-printers, Material, and Software & Services for Surgical Guides & Instruments, Prosthetics & Implants, and Others from 2024 to 2034

Drug Delivery Systems Market

Drug Delivery Systems Market Analysis by Delivery System (Intra Uterine, Pro-drug Implants, Targeted Drug Delivery), by Route of Administration (Oral, Injectable, Inhalation, Ocular, Nasal), by Application (Oncology, Urology, Diabetes), by Region - Global Insights 2022-2032

Malignant Mesothelioma Market

Schedule a Call